Tech Digest

Japan Wakes Up to Its Aging Apocalypse

Stay Up to Date!

Simply enter your email below and click SIGN UP!

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

August 13, 2018

Dear Reader,

For years, I’ve predicted that Japan would be the first nation to wake up to the seriousness of continually increasing lifespans. The unexpected success of the book, The 100-Year Life—Living and Working in an Age of Longevity, in Japan indicates to me that a tipping point has finally been reached.

And its impact will be felt all over the world.

The 100-Year Life was first published in English in 2016. Like my book, The Methuselah Effect, it deals with some of the consequences of an aging society. Also like my book, it didn’t attract a lot of attention.

That changed, however, when the translated version was published in Japan as LifeShift. The Japanese quickly embraced the central message of the book: that individuals, businesses, institutions, and government desperately needed to adapt to the reality of 100-year lifespans.

According to Leo Lewis of the Financial Times, the book transformed public debate and crystallized what had been a murky discussion of demography-themed hopes and fears.

I’ve written in the past about the transformation longer lifespans and low birthrates are causing in Japan. We see abandoned rural towns and urban properties. Prisons convert to assisted-living facilities as the aged commit nonviolent crimes for the sole purpose of being incarcerated. As dementia rates increase with population age, authorities have proposed implanting RFID chips in the toenails of older people who wander around unable to remember their own addresses.

Polls from 2014 showed that almost 90% of Japanese consider aging a problem, compared to only about a quarter of Americans. The need to increase the fertility rate has become standard joke material in the Japanese media.

Most important, the Japanese Ministry of Health, Labour and Welfare deregulated the drug approval process for regenerative medicine, specifically to improve health and healthcare costs for older people. It seems that the Japanese people are not oblivious to the problems of aging, though until recently, the topic was limited mostly to policy makers.

Now aging and methods for dealing with age are mainstream public conversations. The Japanese cultural and psychological revolution I’ve been predicting is happening now. Most significantly, Prime Minister Shinzo Abe has absorbed and integrated the lessons into his economic program, and politicians all over Japan have begun to talk about the need to adapt to longer lives. 

Unfortunately, they haven’t made a complete transition.

Get Ready for 200-Year Lifespans

The Japanese have recognized the continual increase in lifespans that began in the 1800s, but they haven’t yet realized that the rate of increase is exponential. We’re on the verge of solving the issues that have kept maximum lifespans at about 120 years, meaning the end of senescence as we know it today.

Preparing for 100-year lifespans is not enough.

As financial analysts absorb the reality of 100-year lives, many recommend that people work into their 80s if they want a secure future through age 100. The big question, which almost nobody is addressing, is how long you’ll have to work if lifespans are 150, 200, or more years.

Is that crazy talk?

In the last few weeks, there have been major developments in biogerontology. Some of them, I’m even allowed to talk about.

For example, two of the most important people in the field of anti-aging medicine struck a deal that could reshape history. Let’s start with scientist Michael West, sometimes called the father of regenerative medicine. In his career, he’s made the essential discoveries that led to senolytics, telomerase therapy, and pluripotent stem cell therapies.

Now he has founded a new company, AgeX, specifically to reverse aging. Digest that information if you can. He intends to do it by activating the embryonic gene pathways associated with cellular immortality and healing.

The second person is Jim Mellon, the self-made British billionaire and biotech investor. Mellon had already put about $5 million into West’s age-reversal company, but his investment company, Juvenescence Limited, just bought another $43 million from AgeX’s parent company BioTime (*see disclosure below).

Mellon has assembled a team of superstar scientists and executives for his company Juvenescence that I wager will outperform anything Silicon Valley has put together. Here is a short video of Mellon talking about the science of aging.

The fact that he has put so much faith and money in West’s science after extensive due diligence makes me confident that my own analysis is correct.

The timing is also perfect. Japan’s overhauled regulatory system could bring regenerative medicine to its population in a single year, compared to the decade or so it can take in the US and Europe.

I’ve been lobbying West and Mellon to take some breakthrough therapy through the Japanese regulatory system. Japan not only has the oldest demographic in the world, its population is educated, hardworking, and economically and technologically advanced. And now the Japanese public has woken up to its own emergency.

This is great news for the US, Europe, and the rest of the world, which is headed in the same demographic direction as Japan. 

(*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.)

Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics


Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest

Your privacy is very important to us. Please review our Privacy Policy.


« Back to Articles

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

Discuss This


We welcome your comments. Please comply with our Community Rules.


James Corbett

Aug. 18, 10:30 a.m.

200 year lifespans? Exactly who can afford the meds/technology to get there? Only the elite, I’m sure. Us little people will be shuffled off to die in the nursing homes and probably assisted in dying a little quicker.

Willis Smith

Aug. 13, 11:58 a.m.

When I signed up for Tech Digest I thought it would address many areas of leading technical research.  Unfortunately, it seems to be limited to research on aging.  While it may prove to be important in the future, it is not likely to be as near term as other areas where investment opportunities would arise.  So, let’s see what Patrick Cox has to offer in other domains.

Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact


The Mauldin Economics website, Thoughts from the Frontline, The Weekly Profit, The 10th Man, Connecting the Dots, Transformational Technology Digest, Over My Shoulder, Yield Shark, Transformational Technology Alert, Rational Bear, Street Freak, ETF 20/20, In the Money, and Mauldin Economics VIP are published by Mauldin Economics, LLC Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2018 Mauldin Economics